Loading the company…
Loading the company…
No clearances or recalls under the mapped product codes.
All companies · Product and company coverage
In 2025, Osteoremedies reported engagement with 218 surgeons and other clinicians in the states MedaRep covers, worth $62K in consulting, speaking, meals and travel for its device products, the most in Virginia ($13K to 9). Royalties are left out.
Spend tied to a procedure counts the payments whose product names it. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing.Top states by spend: Virginia ($13K, 9 engaged), Indiana ($9,271, 15 engaged), Massachusetts ($6,499, 15 engaged), Texas ($5,883, 28 engaged), Minnesota ($5,649, 2 engaged).
In the last ten years FDA made 11 decisions for Osteoremedies (510(k) clearances, De Novo grants, PMA approvals and supplements) under the product codes MedaRep maps to 0 procedure families, the most in 2025 (2). The latest was on 2026-07-24.
| SPECTRUM® GV Bone Cement |
Decisions under the product codes mapped to the procedure families; devices filed under other codes are not here. Applicants are rolled up to Osteoremedies.